1.2. Pediatrics

A Black Box Warning states that the long-term safety of topical calcineurin inhibitors has not been established, and continuous long-term use is not recommended. While a causal relationship for the incidence of malignancy has not been established, topical calcineurin inhibitor use should be avoided in children younger than 2 years of age as the effect on the developing immune system is not known^1-6.

Recommended pediatric dosages for topical calcineurin inhibitors are summarized in Table 2^1-4.